A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1

Overview

About this study

The purpose of this study is to evaluate the effectiveness, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Has documented diagnosis of primary hyperoxaluria type 1 (PH1).
  • Estimated glomerular filtration rate (eGRF) ≤ 45 mL/min/1.73 m^2 for patients ≥ 12 months of age (< 12 months of age, must have serum creatinine considered elevated for age).
  • Meets plasma oxalate level requirements.
  • If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days.
  • If on dialysis, may be on hemodialysis therapy only and must have been on a stable regimen for at least 4 weeks.

Exclusion Criteria: 

  • Hemodialysis/peritoneal dialysis combination therapy or peritoneal dialysis alone.
  • Diagnosis of conditions other than PH1 contributing to renal insufficiency.
  • History of liver transplant.
  • History of kidney transplant and currently receiving immunosuppressants

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

John Lieske, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20480287

Mayo Clinic Footer